Composition for preventing hair loss or promoting hair growth

Abstract

The present invention relates to a composition for preventing hair loss or promoting hair growth, which contains a component that promotes hair growth or delays hair loss. To confirm this, the present invention confirms the wnt / β-catenin signaling pathway activity promotion effect, hair papilla cell proliferation effect, and β-catenin protein expression amount increase effect through in vitro experiments. Further, it is confirmed that good results are shown in the researcher evaluation after use by clinical photographing and in the evaluation through hair video graph, thereby showing a high hair loss prevention and / or hair growth effect. In view of these comprehensive results, the composition of the present invention has an excellent hair loss prevention and / or hair growth promotion effect.

Description

TECHNICAL FIELD

[0001] The present application relates to a composition for promoting hair growth or preventing hair loss, and relates to a composition for preventing hair loss or promoting hair growth, which contains a component inducing promotion of hair growth and / or prevention of hair loss. BACKGROUND

[0002] With the change of times, in the process of increasing attention to beauty, hair occupies an important part. Hair is a fine and keratinized structure produced on the surface of the skin. This not only has a buffering effect on external impact, but also plays a function of protecting the human body from external stimuli such as direct light, cold, friction, danger, and heavy metals such as arsenic, mercury, and zinc that are harmful to the body are discharged to the outside of the body, and is emphasized in the beauty aspect of decoration in modern times.

[0003] However, there are more and more people complaining about hair loss due to various reasons including changes in dietary life and increases in internal and external stress. It is well known that for hair loss, genetic factors are the most important cause, but as described above, increases in social stress, environmental pollution, frequent perming and dyeing, or incorrect scalp management are also becoming causes of hair loss.

[0004] A person's hair is about 100,000 to 150,000 or so, and each hair has a different growth cycle from each other.

[0005] The formation of the initial hair follicle is formed by the basal layer of the epidermal cells under the action of β-catenin (Sarah E. Miller, 2002), and the dermal fibroblasts receiving signals from the formed placode form a dermal condensate. At the same time, the placode grows, sinks into the dermis, and combines with the dermal condensate to form a primary hair germ. The epidermal cells that form the hair germ grow long in the direction of the developing dermis, forming a long columnar structure composed of multiple layers, i.e., a hair peg, and at the same time, the dermal condensate forms a spherical hair papilla (dermal papilla). The end of the hair peg gradually thickens to form a hair bulb, the hair bulb forms a form that encloses the hair papilla, completes the hair follicle, and the epidermal cells inside the hair follicle differentiate to produce hair.

[0006] The initially produced hair goes through the following cycle: after the growth period, it enters the regression period, the resting period, and then the hair falls out, and then enters the growth period again.

[0007] The hair growth cycle consists of three stages, classified as anagen stage, which is the most active growth period of the hair, catagen stage, which is the period when the hair begins to degenerate, and telogen stage, which is the period when the hair growth stops or enters a resting state.

[0008] It is known that, in regulating this hair growth cycle, the activity of hair papilla cells that constitute hair follicles and outer root sheath cells (outer root sheath cells) including hair follicle stem cells, and various cytokines and growth factors produced in these cells play an important role. It is known that, for periodic hair growth, regeneration of hair follicles and activation of stem cells must be achieved, which is achieved by the production and activation of Wnt / β-catenin (Ito M, Yang Z, Andl T, Cui C, Kim N, Millar SE, and Cotsarelis G, Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature, 2007, 447(7142): p.316-320). When the hair follicle cycle circulates from the telogen stage to the active stage (anagen stage), the Wnt signal mediates and determines the state of the active stage hair follicle.

[0009] In general, alopecia refers to a condition in which the proportion of hair in the growth stage decreases and the proportion of hair in the catagen or telogen stage increases in this cycle, thereby abnormally increasing the amount of hair loss. For a normal person, there are many hairs in the growth stage, whereas for a person suffering from alopecia, there are many hairs in the telogen stage, and thus a macroscopically visible hair loss phenomenon occurs. A person who has alopecia is characterized by miniaturization of hair. As alopecia progresses, the time of the growth stage is shortened, promoting transition to the catagen and telogen stages, and then the volume of the hair papilla becomes small, and the hair follicle gradually miniaturizes. Therefore, in order to treat alopecia, it is important to rapidly restore the telogen stage hair follicle to the growth stage and to extend the shortened growth stage.

[0010] As a cause of alopecia, male hormone overaction theory, sebum overproduction theory, poor blood circulation theory, head skin function decline theory caused by peroxide, bacteria, etc., genetic factors, aging, stress, etc. have been proposed, but the cause of alopecia has not been clearly revealed so far. For such a variety and complexity of alopecia causes, the alopecia prevention products known so far contain ingredients such as those for the purpose of promoting blood circulation, strengthening hair root function, moisturizing the scalp, preventing dandruff, antioxidant effect, prolonging the hair growth period, or inhibiting male hormone as effective ingredients, but the fact is that there has been no significant effect so far, and the problem of side effects has also been raised.

[0011] As a preparation for the treatment or prevention of alopecia developed so far, there are preparations in which female hormones for inhibiting male hormones, moisturizing the scalp, and strengthening hair root function are the main ingredients, or preparations containing minoxidil, finasteride, trichosaccharide, etc.

[0012] However, commercially available preparations have many limitations in use due to no effect on already progressed alopecia, side effects such as inhibition of male hormones, or precautions for use. SUMMARY

[0013] TECHNICAL PROBLEM

[0014] The problem to be solved by the present application is to provide a composition for preventing alopecia or promoting hair growth which is safe for the human body and has no side effects, while having excellent effects of promoting hair growth and / or preventing alopecia.

[0015] In addition, the problem to be solved by the present application is to provide a hair or scalp product containing the above-mentioned composition for preventing alopecia or promoting hair growth.

[0016] TECHNICAL SOLUTION

[0017] The present inventors have made persistent efforts to develop a composition which has no disadvantages such as weak effects of preventing alopecia or promoting hair growth of the conventional alopecia treatment agent and is safe for the human body while being effective.

[0018] As a result, it was found that a composition containing any one or more of Valechlorine, Tussilagone, Periplocin, Lysionotin, Nitidine, Lanosterol, Engeletin, Specnuezhenide, Praeruptorin B, Rotundic acid, Sesamoside, Polyphyllin VII, or a pharmaceutically or cosmetically acceptable salt thereof as an effective ingredient has an effect of promoting hair growth and / or an effect of preventing hair loss, thereby completing the present application.

[0019] Specifically, the inventors of the present application confirmed that each of the above effective ingredients promotes the activity of the Wnt / β-catenin signaling pathway, promotes the proliferation of hair papilla cells, and increases the expression of β-catenin in hair papilla cells. That is, it was confirmed through in-vitro experiments that each of the above effective ingredients promotes the activity of the Wnt / β-catenin signaling pathway, promotes the proliferation of hair papilla cells, and increases the expression of β-catenin in hair papilla cells, and plays an important role in transitioning the physiological cycle of hair from the catagen phase or even the telogen phase to the anagen phase (active phase).

[0020] The composition for preventing hair loss and / or promoting hair growth of the present application is expected to shorten the period of time from the telogen phase to the anagen phase in the growth cycle of hair due to these effects, thereby promoting the growth of hair and slowing down the transition to the catagen phase, thereby preventing hair loss. However, the present application is not limited to this mechanism.

[0021] In addition, the inventors of the present application confirmed that, when a cosmetic composition containing the above effective ingredients is applied to a patient with alopecia, it has a remarkably superior effect in improving the thickness and density of hair.

[0022] Additionally, the results of a comparative experiment with a commercially available product, i.e., minoxidil, confirmed that the composition of the present application containing the above effective ingredients has a significantly superior effect of preventing hair loss and / or promoting hair growth compared to minoxidil.

[0023] The present application provides a composition for preventing hair loss or promoting hair growth, which contains any one or more of Valechlorine, Tussilagone, Periplocin, Lysionotin, Nitidine, Lanosterol, Engeletin, Specnuezhenide, Praeruptorin B, Rotundic acid, Sesamoside, Polyphyllin VII, or a pharmaceutically or cosmetically acceptable salt thereof as an effective ingredient.

[0024] The above 12 effective ingredients have the chemical formula or pharmaceutically or cosmetically acceptable salt structure described in Table 1 below.

[0025] [Table 1]

[0026]

[0027]

[0028]

[0029] In one embodiment, the above 12 effective ingredients can be plant-derived ingredients.

[0030] The above chlorinated valerian (Valechlorine) can be an ingredient derived from valerian (Valeriana officinalis L.), the above tussilagone can be an ingredient derived from coltsfoot (Tussilago farfara), the above periplocin can be an ingredient derived from periploca (Periploca sepium Bge), the above lysionotin can be an ingredient derived from fewflower lysionotus herbs, the above nitidine can be an ingredient derived from Zanthoxylum nitidum (Roxb.) DC., the above lanosterol can be an ingredient derived from Portulaca oleracea L., the above engeletin can be an ingredient derived from Engelhardtia roxburghiana Wall, the above specnuezhenide can be an ingredient derived from privet fruit (Ligustrum lucidum extract / privet fruit extract), the above praeruptorin B can be an ingredient derived from Peucedanum praeruptorum Dunn, the above rotundic acid can be an ingredient derived from Euscaphis japonica, the above sesamoside can be an ingredient derived from Sesamum angolense, and the above polyphyllin VII can be an ingredient derived from Paris polyphylla.

[0031] In one embodiment, the content of any one or more of the above chlorinated valerian, tussilagone, periplocin, lysionotin, nitidine, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotundic acid, sesamoside, polyphyllin VII, or pharmaceutically or cosmetically acceptable salts thereof, can be 0.00001 to 50% by weight, preferably 0.0001 to 20% by weight, more preferably 0.001 to 10% by weight, even more preferably 0.01 to 5% by weight, relative to the total weight of the composition.

[0032] In addition, the present application provides a pharmaceutical (pharmaceutics), a quasi-pharmaceutical product, or a cosmetic product, which comprises the above-mentioned composition for preventing hair loss or promoting hair growth. The composition of the present application can also be generally formulated into any form applicable to the skin, but is preferably formulated into the form of an external agent. The composition of the present application can be prepared into a formulation applicable to the skin, such as a liquid, a cream, a paste, or a solid, etc.

[0033] Any one or more of chlorogenic acid, faradiol, oleandrin, daurisoline, rottlerin, lanosterol, engelitin, vitexin, prunellin, ilexgenin A, euphorbiin, chloranthin VII, or a pharmaceutically or cosmetically acceptable salt thereof of the present application can be included in the above-mentioned composition or formulation as a hair loss preventing agent and / or a hair growth promoting agent.

[0034] In one embodiment, when the formulation of the present application is a liquid, a solvent, a solubilizer, or an emulsion agent, etc. can be used as a carrier component. For example, water, alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty ester, polyethylene glycol, or fatty acid ester of sorbitan, etc. can be used as a carrier component.

[0035] The above-mentioned alcohol refers to one or more of alcohols, and is preferably a linear or branched C2-C4 monoalcohol, and more preferably, ethanol or isopropyl alcohol can be used. In particular, if ethanol or isopropyl alcohol is used as a carrier component, the transdermal absorption of the composition for preventing hair loss or promoting hair growth can be promoted.

[0036] In one embodiment, when the formulation of the present application is a paste, a cream, or a gel, an animal oil, a vegetable oil, a wax, a paraffin, starch, tragacanth gum, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide, etc. can be used as a carrier component.

[0037] In one embodiment, when the formulation of the present application is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder, etc. can be used as a carrier component. In particular, when it is a spray formulation, a propellant such as chlorofluorocarbon, propane / butane, or dimethyl ether, etc. can be additionally included.

[0038] In one embodiment, in addition to any one or more of chlorinated valerin, coltsfoot ketone, salicylic acid, genistein, zeaxanthin, lanosterol, scutellarin, privetin, imperatorin, ferruginic acid, sesamoidin, Paris saponin VII, or their pharmaceutically or cosmetically acceptable salts, the composition of the present invention may also include ingredients commonly used in topical agents applicable to the skin. For example, it may additionally include one or more additives selected from the group consisting of water, surfactants, humectants, lower alcohols, chelating agents, bactericides, antioxidants, preservatives, pigments, and fragrances.

[0039] The present invention provides a hair or scalp product comprising the above-described composition for preventing hair loss or promoting hair growth.

[0040] The aforementioned hair or scalp products may be selected from any of the following groups: shampoo, tonic, conditioning agent, lotion, serum, ampoule, treatment, mousse, gel, hair mask, cream, essence, powder, spray, oil, soap, and ointment, but are not limited thereto.

[0041] In addition, the aforementioned hair or scalp products may be selected from any of the following groups: cleansers, hair dyes, perming agents, hair styling agents, scalp treatments, hair treatments, scalp removers, hair removers, scalp massagers, hair massagers, scalp care products and hair care products, or their aerosol-type forms, but are not limited thereto.

[0042] In one embodiment, the composition of the present invention for preventing hair loss or promoting hair growth can be prepared as a hair tonic or hair lotion dosage form.

[0043] The composition of the present invention for promoting hair growth is preferably used by transdermal administration methods such as direct application or spraying onto the skin.

[0044] In addition, the present invention provides a method for preventing hair loss or promoting hair growth, comprising the step of administering a composition for preventing hair loss or promoting hair growth to a patient (subject), the composition comprising one or more of the following as active ingredients: chlorinated valerin, coltsfoot ketone, salicylic acid, styracin, stigmacanoidin, lanosterol, stigmacanoidin, privetin, angelica dahurica, ferruginic acid, sesamoidin, Paris polyphylla saponin VII, or pharmaceutically or cosmetically acceptable salts thereof.

[0045] The term "administration" used in the present invention can mean introduction of the composition of the present invention by any appropriate method. For the administration route of the composition of the present invention, it can be administered by any general route, as long as it can reach the target tissue. It can be preferably administered transdermally or orally, preferably transdermally, wherein topical application is most preferred. The number of applications of the composition of the present invention can be determined according to the prescription, need or desire.

[0046] All of the ingredients described in the present invention are preferably not more than the maximum use value prescribed in the relevant regulations, standards (e.g., the relevant regulations such as the cosmetic safety standards (Korea), the cosmetic safety technical standards (China), the food code (Korea), the food additive code (Korea), the health functional food code (Korea), the health standards (China)) and the like of Korea, China, the United States, Europe, Japan and the like. That is, preferably, the cosmetic or personal care composition of the present invention contains the ingredients of the present invention within the content limit allowed in the relevant regulations and standards of each country.

[0047] The present invention confirmed through in vitro experiments that any one or more of valtrinate, faradiol, rottlerin, daurin, ruscogenin, lanosterol, engelitin, vitexin, praeparin, ilexgenin A, plumbagin, chloranthin VII, or pharmaceutically or cosmetically acceptable salts thereof contained in the composition of the present invention plays an important role in expanding the Wnt / β-catenin signaling of the hair papilla cells, thereby playing an important role in the physiological cycle of hair from the catagen phase to the anagen phase (Experimental Examples 1, 2 and 3).

[0048] The use amount of the composition of the present invention can be appropriately adjusted according to individual differences in age, the degree of lesions, and the like, or the dosage form, and it is generally preferred to apply an appropriate amount to the scalp 1 to several times a day, and use for 1 week to several months. In the experimental examples of the present invention, the hair loss treatment and / or hair growth composition 1 was used 5 times a week for 6 months, and as a result, it was confirmed that an excellent hair growth promoting effect was exhibited (Experimental Example 4).

[0049] Effects of the Invention

[0050] The composition for preventing hair loss and / or promoting hair growth of the present invention has an excellent hair growth effect, and also has an excellent effect of preventing / delaying hair loss. BRIEF DESCRIPTION OF DRAWINGS

[0051] Figure 1 is a graph showing the activity measurement results of the Wnt / β-catenin promoter of daurin, ruscogenin, ilexgenin A or vitexin.

[0052] Figure 2is a graph showing the results of the activity measurement of the Wnt / β-catenin promoter by peucedanin, valtratin chloride, lanosterol, or paris saponin VII.

[0053] Figure 3 is a graph showing the results of the activity measurement of the Wnt / β-catenin promoter by peucedanin, valtratin chloride, lanosterol, or paris saponin VII. DETAILED DESCRIPTION

[0054] Hereinafter, examples and the like will be described in detail in order to help the understanding of the present application. However, the embodiments of the present application can be modified in various different forms, and the scope of the present application should not be interpreted as being limited to the following examples. The embodiments of the present application are provided in order to more completely explain the present application to those having ordinary skill in the art.

[0055] Preparation Example 1: Composition 1 for hair loss treatment and / or hair growth promotion (hair tonic)

[0056] A hair tonic composition containing valtratin chloride, peucedanin, periandrin, daurin, robustaferine, lanosterol, engelitin, filipendulin, decursinol, ilexguercin, robustaferine, or paris saponin VII as an effective ingredient was prepared according to the prescription shown in Table 2 below by a conventional method as Examples 1 to 12-2.

[0057] Materials and reagents used in the experiments of the present application were purchased from cosmetic raw material manufacturers and commercial suppliers and used as they were.

[0058] [Table 2]

[0059]

[0060]

[0061] Preparation Example 2: Composition 2 for hair loss treatment and / or hair growth promotion (hair lotion)

[0062] Valtratin chloride, peucedanin, periandrin, daurin, robustaferine, lanosterol, engelitin, filipendulin, decursinol, ilexguercin, robustaferine, or paris saponin VII was prepared according to the prescription shown in Table 3 below by a conventional method as a hair lotion.

[0063] [Table 3]

[0064]

[0065] Experimental Example 1: Hair papilla cell activity signal (Wnt / β-catenin) regulation effect

[0066] In general, Wnt / β-catenin signaling activated in the hair papilla occurs during the transition from the catagen or telogen phase to the anagen phase in the growth cycle of the hair, i.e., during the entire anagen phase in which the hair begins to grow. In addition, in the telogen or catagen phase, the Wnt / β-catenin signaling is weakened or disappears, and thus the phenomenon of hair follicle degeneration and hair loss occurs.

[0067] Accordingly, in the present experiment, the contribution of chlorovalumin, faradiol, periandrin, rockberg, rindling, lanosterol, engelitin, acaciin, prunusin, ilexolic acid, or chloranthin VII of the present application to the amplification of Wnt / β-catenin signaling was investigated.

[0068] In the present experiment, DMSO was used as a negative control group.

[0069] In a culture 96-well plate, Wnt reporter HEK293A cells 3 x 10 4 After seeding in each well, chlorovalumin, faradiol, periandrin, rockberg, rindling, lanosterol, engelitin, acaciin, prunusin, ilexolic acid, or chloranthin VII of the present application was treated at a concentration of 200 μg / ml, 20 μg / ml, 2 μg / ml, 0.2 μg / ml, respectively. Thereafter, reporter assay was performed using a luciferase assay kit (E1960) of Promega. The experiment was performed according to the experimental method of the manufacturing company, and the activity of the Wnt / β-catenin promoter was measured using a luminometer Victor (PerkinElmer, Waltham, MA, USA). The measurement results are shown in Figure 1 、 Figure 2 and Figure 3

[0070] As a result, chlorovalumin, faradiol, periandrin, rockberg, rindling, lanosterol, engelitin, acaciin, prunusin, ilexolic acid, or chloranthin VII amplified the Wnt / β-catenin signaling by about 2 times or more compared to the untreated group, i.e., the negative control group.

[0071] ​Accordingly, it was confirmed that chlorovalumin, faradiol, rottlerin, daurisoline, rabdosin, lanosterol, engelitin, prenylflavonoid, prunusin, ilexgenin, or chloranthin very excellently promoted the activity of the Wnt / β-catenin signaling pathway, which is a hair follicle stem cell hair growth promotion signal, thereby having a hair growth promotion effect.

[0072] Experimental Example 2: Effect of promoting hair papilla cell proliferation

[0073] In this experiment, the effect of promoting hair papilla cell proliferation was confirmed using human hair papilla cells (dermal papilla cells, DPCs). The human hair papilla cells were purchased from the PromoCell company. The above DPCs were cultured in a culture solution (Follicle Dermal Papilla Cell Growth Medium; PromoCell, Heidelberg, Germany) and a culture solution additive (Supplement Mix; PromoCell, Heidelberg, Germany) recommended by the PromoCell company at 37°C and 5% CO2. The cultured DPCs 3,000 cells / well were dispensed into a 96-well plate, and then cultured for 24 hours under 0.1% serum conditions. Thereafter, in the cultured cells, DMSO (vehicle) diluted 1:1000 in serum-free DMEM was used as a control group, minoxidil 0.1 μg / ml was used as a positive control group, and chlorovalumin, faradiol, rottlerin, daurisoline, rabdosin, lanosterol, engelitin, prenylflavonoid, prunusin, ilexgenin, or chloranthin was treated at 2 or 20 μg / ml, respectively, for 1 day and incubated. After the incubation, the degree of proliferation of the cells was evaluated using a CCK method. CCK-8 was treated at 1:10 in the culture solution and incubated for 1 hour. After 1 hour, the absorbance of each well was measured at 450 nm. All experiments were repeated 3 times, and the average of the absorbance values was calculated. For the above results, the control group was set to 100, and it was expressed as a percentage with respect to the control group for the treated group.

[0074] As a result, when chlorovalumin, faradiol, rottlerin, daurisoline, rabdosin, lanosterol, engelitin, prenylflavonoid, prunusin, ilexgenin, or chloranthin was treated, an excellent effect of promoting hair papilla cell proliferation was exhibited (Table 4).

[0075] [Table 4]

[0076]

[0077] Experimental Example 3: Increase in the expression of β-catenin in hair papilla cells

[0078] In the hair papilla cells in the resting phase or regressive phase in which Wnt signal is inhibited, β-catenin is decomposed by GSK3-β. However, in the active phase hair papilla cells in which Wnt signal is amplified, since the activity of GSK3-β is inhibited, β-catenin cannot be decomposed, and thus the expression amount thereof is increased.

[0079] Human hair papilla cells were dispensed at 500,000 cells / well in a 6-well plate, and then valosin chloride, faradiol, rottlerin, daurin, acetylcholine, lanosterol, heparin, vitexin, praepariflavin, ilexgenin A, or chloranthin VII was treated at 2 or 20 μg / ml, respectively, for 1 day and incubated. After the incubation, the cells were disrupted using M-PER lysis buffer (lysis buffer), and an equal amount of cell lysate was loaded into an SDS-PAGE gel. The cell lysate loaded into the SDS-PAGE gel was transferred to a nitrocellulose membrane, and then an anti-beta catenin antibody was pasted to the nitrocellulose membrane, and the protein was detected. GAPDH was used as a control for the amount of protein. The amount of β-catenin increased by valosin chloride, faradiol, rottlerin, daurin, acetylcholine, lanosterol, heparin, vitexin, praepariflavin, ilexgenin A, or chloranthin VII was confirmed, and for the results thereof, in the case where the control group was set to 100, it was expressed as a percentage of the treated group with respect to the control group, and is shown in Table 5.

[0080] [Table 5]

[0081]

[0082] As a result, it could be confirmed that in the group treated with valosin chloride, faradiol, rottlerin, daurin, acetylcholine, lanosterol, heparin, vitexin, praepariflavin, ilexgenin A, or chloranthin VII, the amount of β-catenin was very significantly increased compared to the untreated group, which means that the Wnt / β-catenin signal of the hair papilla cells was increased. In particular, it was confirmed that a more excellent efficacy than the positive control group Wnt3a protein, which binds to the direct receptor of Wnt / β-catenin, was exhibited. (It is generally recognized in the industry that if an increase of 1.5 times or more is shown, there is a hair growth promoting effect.)

[0083] Experimental Example 4: Confirmation of hair growth effect of hair loss treatment or hair growth composition 1 (hair tonic)

[0084] The hair growth effect of the hair loss treatment or hair growth composition 1 (hair tonic) of the present application was tested on a total of 135 men and women who had noticeably less hair than normal or had weak hair with symptoms of hair loss. The scalp areas of the total of 135 men and women were divided into left and right sides, and different compositions were applied to the left and right sides. The 10 men and women were divided into 27 groups, and Comparative Examples 1, 2, 3, and Experimental Examples 1 to 12-2 were used 5 times a week for 6 months on the hair and scalp. After use, a researcher evaluation by clinical photograph and an evaluation by phototrichogram were performed. The researcher evaluation by clinical photograph was performed 4 months and 6 months after application, and for the comparative and experimental examples, the evaluation was performed in 3 items of "good", "slight", and "no change" (good: 50 to 75% improvement, slight: 25 to 50% improvement, no change: no change). The evaluation of the number of hairs per unit area and the average hair thickness by phototrichogram was measured 4 months and 6 months after application, and for the comparative and experimental examples, the results are shown in Table 6.

[0085] [Table 6]

[0086]

[0087]

[0088] From the above results, it can be seen that a higher hair loss prevention and hair growth effect was confirmed in Experimental Examples 1 to 12-2 containing valtrinate chloride, tussilagone, rottlerine, sabinaline, rabdosin, lanosterol, engelitin, prenylflavonoid, prunol, ilexolic acid, or chloranthin saponin VII.

[0089] Thus, it was proven that the composition for preventing hair loss or promoting hair growth of the present application containing valtrinate chloride, tussilagone, rottlerine, sabinaline, rabdosin, lanosterol, engelitin, prenylflavonoid, prunol, ilexolic acid, or chloranthin saponin VII as an effective ingredient can be very effectively used for treating hair loss.

[0090] The above examples of dosage forms such as hair tonics or shampoos are only examples of the composition for promoting hair growth of the present application, and it is obvious to those skilled in the art that the scope of the composition of the present application is not limited only to these dosage forms.

[0091] As described above, it was confirmed that chlorogenic acid, shikimic acid, tylophorine, dauricin, rindling, lanosterol, engelitin, acaciin, prunusin, ilexolic acid, hupehenoside or chonglou saponin VII have excellent effects of inducing hair growth and inhibiting hair loss, and the composition for preventing hair loss or promoting hair growth of the present application is prepared into various dosage forms. The dosage form examples such as hair tonics or shampoos are specifically described above. However, these dosage form examples are only examples of the composition of the present application, and it is obvious to those skilled in the art that the scope of the composition of the present application is not limited only to these dosage forms.

[0092] In addition, examples of the shampoo composition of the present application are shown in Table 7 below, and examples of the conditioner composition are shown in Table 8 below.

[0093] [Table 7]

[0094]

[0095] [Table 8]

[0096]

Claims

1. A composition for preventing hair loss or promoting hair growth, comprising periplocin as an effective ingredient, and comprising any one or more of tussilagone, nitidine, lysionotin, valechlorine, engeletin, specnuezhenide, praeruptorin B, rotundic acid, sesamoside, polyphyllin VII, or pharmaceutically or cosmetically acceptable salts thereof as an optional effective ingredient.

2. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein The above composition promotes the activity of Wnt / β-catenin signaling pathway.

3. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein The above composition promotes the proliferation of hair papilla cells.

4. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein The above composition increases the expression of β-catenin in hair papilla cells.

5. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein The above composition is used for a medical external product or for a cosmetic.

6. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein The above composition is used for a medicine.

7. A hair or scalp product comprising the composition for preventing hair loss or promoting hair growth according to claim 1.

8. A hair or scalp product as claimed in claim 7 wherein, The above product is selected from the group consisting of a shampoo, a tonic, a conditioner, a hair rinse, an essence, a vial, a hair cream, a mousse, a gel, a hair pack, a cream, an essence, a powder, a spray, an oil, a soap, and an ointment.

9. A hair or scalp product as claimed in claim 7 wherein, The above product is selected from the group consisting of a cleanser, a hair dye, a hair perm, a hair styling agent, a scalp treatment agent, a hair treatment agent, a scalp detergent, a hair detergent, a scalp massage agent, a hair massage agent, a scalp care agent, and a hair care agent. The above product is selected from the group consisting of a cleanser, a hair dye, a hair perm, a hair styling agent, a scalp treatment agent, a hair treatment agent, a scalp detergent, a hair detergent, a scalp massage agent, a hair massage agent, a scalp care agent, and a hair care agent.

Images